Santen Pharmaceutical Valuation
Is 4536 N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4536 N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4536 N (MX$339.23) is trading above our estimate of fair value (MX$183.06)
Significantly Below Fair Value: 4536 N is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4536 N?
Key metric: As 4536 N is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 4536 N's PS Ratio? | |
|---|---|
| PS Ratio | 1.6x |
| Sales | JP¥279.04b |
| Market Cap | JP¥466.55b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 28.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 4536 N's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2x | ||
LAB B Genomma Lab Internacional. de | 1.4x | 9.9% | Mex$25.2b |
ROVI Laboratorios Farmaceuticos Rovi | 4x | 11.4% | €3.2b |
BHC Bausch Health Companies | 0.3x | 1.5% | US$3.1b |
600062 China Resources Double-Crane PharmaceuticalLtd | 2.1x | 8.9% | CN¥21.9b |
4536 N Santen Pharmaceutical | 1.6x | -0.4% | Mex$466.5b |
Price-To-Sales vs Peers: 4536 N is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (1.9x).
Price to Sales Ratio vs Industry
How does 4536 N's PS Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 192 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 192 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 4536 N is good value based on its Price-To-Sales Ratio (1.6x) compared to the Global Pharmaceuticals industry average (2.4x).
Price to Sales Ratio vs Fair Ratio
What is 4536 N's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4536 N's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
ROVI N
€1,416.38
7D
0%
1Y
54.7%
ICON
US$15.7b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR N
US$4,286.08
7D
3.3%
1Y
-7.7%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%